Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04975698 · ClinicalTrials.gov registry record · Phase 2
HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903
A Phase 2 study of HIV Associated Lymphoma, sponsored by Catherine Bollard.
- Active
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 11
- Study locations
NCT04975698 is a Phase 2 study of HIV Associated Lymphoma that is active but no longer recruiting, run by Catherine Bollard. The registered enrollment target is 12 participants. The trial reports 11 study locations across 9 states.
The verdict
NCT04975698, a Phase 2 study of HIV Associated Lymphoma, is active but no longer recruiting, sponsored by Catherine Bollard.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a Phase II multi-center trial single arm trial of autologous transplantation (ASCT) followed by administration of HST-NEETs for treatment of HIV associated lymphoma
Conditions Studied
Interventions
- BIOLOGICAL HST-NEETs
- BIOLOGICAL Bone Marrow Transplant
Study Locations (11)
New York
- Icahn School of Medicine at Mount Sinai - New York
- Memorial Sloan Kettering (MSKCC) - New York
Texas
- Baylor College of Medicine - Houston
- MD Anderson - Houston
California
- City of Hope National Medical Center - Duarte
District of Columbia
- Georgetown - Washington D.C.
Florida
- H. Lee Moffitt Cancer Center - Tampa
Georgia
- Northside - Atlanta
Illinois
- University of Illinois - Chicago
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-10-25 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04975698
The ClinicalTrials.gov registry entry for NCT04975698 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Catherine Bollard, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Associated Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which HST-NEETs is the first listed.
NCT04975698 reports 11 study locations spanning 9 distinct geographic areas - top geographies include New York, Texas, California.
Frequently Asked Questions
What is clinical trial NCT04975698 about?
NCT04975698 is a clinical study titled "HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903". This is a Phase II multi-center trial single arm trial of autologous transplantation (ASCT) followed by administration of HST-NEETs for treatment of HIV associated lymphoma
What is the current status of trial NCT04975698?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-10-25. Estimated completion is 2026-06.
What conditions does trial NCT04975698 study?
This clinical trial studies the following conditions: HIV Associated Lymphoma.
What interventions are being tested in trial NCT04975698?
The interventions under investigation include: HST-NEETs (BIOLOGICAL), Bone Marrow Transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT04975698?
This trial is sponsored by Catherine Bollard, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04975698 being conducted?
This trial has 11 study locations across California, District of Columbia, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.